European Innovation Council

ELEM is a start-up company conceived at the Barcelona Supercomputing Center (BSC) and host of MareNostrum supercomputer. ELEM is co-founded by BSC researchers Mariano Vázquez, Guillaume Houzeaux, José María Cela, and business consultant Chris Morton. The company has developed Alya Red, a set of simulation tools, which following a “Software-as-a-Service” model deployed in the cloud, focuses on medical devices and pharmaceutical industries. Alya Red simulates cardiovascular or respiratory systems on “virtual patients”. Combining high performance computing, computational biomechanics and data analysis, these computational avatars can be used by biomedical sector companies and clinicians to elaborate diagnoses, plan treatments, improve drug delivery and action, optimise medical devices, etc. ELEM headquarters are in Barcelona.

Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.

New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.

New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.

Saalg Geomechanics is owner and operator of an engineering company intended to offer specialized advanced geological and numerical services. The company offers numerical model calibrations and soil and rock parameters characterization by backanalysis and inverse analysis, 2D and 3D geomechanical and geotechnical simulations, manily for TBM Tunnel Excavations, Conventional Tunnels, Large and deep excavations, reinforced earth retaining walls and wellbore stabity analysis, enabling their customers to build a bridge between academic research in the field of geomechanics and the industry.

Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.

Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

bound4blue specializes in the development of innovative foldable and autonomous wingsail systems designed for integration into a variety of vessels. This technology serves as a complementary propulsion system, harnessing wind power to generate thrust and significantly reducing the reliance on main engine power. As a result, bound4blue's wingsails can lead to reductions in fuel consumption and pollutant emissions by up to 40%. In addition to improving environmental sustainability, the system offers a payback period of less than five years, making it an economically viable option for boat operators. The technology also facilitates the production of hydrogen and oxygen through the electrolysis of seawater, further enhancing its eco-friendly credentials.

Roka Furadada mission is to reduce the incidence of skin cancer through research, development, and production of active ingredients and medical devices, with high efficiency and low toxicologic and environmental impact.

NEOS Surgery S.L. is a Barcelona-based company specializing in the research, design, development, and commercialization of implantable medical devices for neurosurgery. Founded in 2003, NEOS focuses on innovative solutions for cranial and spinal surgical applications, including its proprietary BHID cranial fixation system, which is designed for placement in the burr hole of a craniotomy. The company is committed to meeting the needs of neurosurgeons and patients, ensuring its products are both effective and compliant with stringent quality standards, including ISO certifications. By capturing market demands, NEOS aims to create high-value medical devices that enhance surgical outcomes and contribute to advancements in the neurosurgery field.

X1 Wind is a disruptive floating platform developing a floating wind platform for deep waters. The platform has redesigned floating wind platforms to reduce costs by 50percent and weight 80percent while expanding the operation depth range in comparison to other floating solutions. It has less active systems than current designs and can be fully assembled at the port and then installed using a small tug boat. X1 Wind helps to achieve a radical weight reduction in floating wind structures to current semi-submersible and spar systems. It was founded in 2017 and is based in Barcelona, Spain.

X1 Wind is a disruptive floating platform developing a floating wind platform for deep waters. The platform has redesigned floating wind platforms to reduce costs by 50percent and weight 80percent while expanding the operation depth range in comparison to other floating solutions. It has less active systems than current designs and can be fully assembled at the port and then installed using a small tug boat. X1 Wind helps to achieve a radical weight reduction in floating wind structures to current semi-submersible and spar systems. It was founded in 2017 and is based in Barcelona, Spain.

Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.

Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.

Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.

Revolutionary electromagnetic endoscopy accessory to automatize polyp detection

Revolutionary electromagnetic endoscopy accessory to automatize polyp detection

Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.

omni:us is a developer of insurance claims automation software that leverages advanced artificial intelligence and natural language processing to enhance the efficiency of claims processing. The omni:us Platform allows insurers to create customized modules and swiftly integrate AI into their operations through the Cognitive Claims Kit, which addresses various use cases along the claims value chain, including document intake and coverage verification. The software is designed to work seamlessly with legacy systems, requiring no in-house AI expertise for implementation. By utilizing handwritten text recognition technology, omni:us automates data-intensive workflows and generates comprehensive claims profiles. The company aims to foster a hybrid workflow where human and machine collaboration enhances productivity. Headquartered in Berlin, omni:us has a research partnership in Barcelona and maintains a presence in the UK, France, and the United States, serving clients such as Allianz, Baloise, and AmTrust.